What You Should Know:
– Folia Health, the patient-driven health company and pioneer of home-reported outcomes (HROs), committed to transforming lived experiences into structured data insights to advance research and personalized care, today announced the close of a $10.5 million in Series A funding round led by S3 Ventures, alongside longtime partner Crosslink Capital and specialist fund Create Health Ventures.
– The investment will enable the company to double down on its mission to put power in the hands of patients, whose firsthand experiences with chronic and rare conditions make them valuable — and underutilized — healthcare experts.
S3 Ventures Leads Investment in Folia Health to Advance Patient-Driven Real-World Evidence
Founded in 2005, S3 Ventures is one of the largest and longest-standing venture capital firms in Texas. Backed by a philanthropic family foundation with multi-billion-dollar assets, S3 Ventures provides patient capital and resources to visionary founders building high-impact companies across Business Technology, Digital Experiences, and Healthcare Technology. With more than $900 million under management, the firm leads Seed, Series A, and Series B rounds ranging from $500K to $10M, with capacity to invest $20M+ throughout a company’s growth.
Folia Health has developed a platform that empowers individuals to track symptoms, treatments, and outcomes — and share them with unprecedented control. Centered on consent and radical transparency, the platform ensures that:
- Data used in research requires explicit participant consent.
- Contributors can see exactly how their information is applied through detailed Participant Reports.
- Participation is always voluntary, with the option to withdraw at any time.
- Patients are recognized for their contributions via Folia’s revenue-sharing program, Data Dividends.
“This funding is an affirmation of our fierce dedication to making patient-focused healthcare a reality,” said Nell Meosky Luo, Founder and CEO of Folia Health. “Instead of trying to fix the system from the outside in, we’ve built Folia to harness the power of each individual patient — to make their healthcare make sense.”
By giving direct value back to patients, Folia generates high-quality, longitudinal real-world evidence (RWE) that informs FDA discussions, shapes treatment guidelines, and fuels collaborations with leading life sciences companies. Its research-grade data has already driven insights across high-impact conditions including lupus, sickle cell disease, eczema, and paroxysmal nocturnal hemoglobinuria (PNH).
Key initiatives include:
- Active studies in rare kidney diseases with a major life sciences partner.
- A national study evaluating the impact of Trikafta in cystic fibrosis.
- The first app-based, remote study capturing daily experiences of people with IgA nephropathy.
- Longitudinal sickle cell research addressing disparities and pain management challenges.
The funding announcement follows Folia’s launch of Mosaic, a community insights initiative that allows participants to ask questions and receive answers from aggregated, condition-specific data. Currently available for eczema and PNH, Mosaic will expand to lupus and sickle cell disease in 2026.
